Author

Wen-Zhe Si

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis

This study aimed to synthesize evidence from recent randomized controlled trials (RCTs) evaluating the efficacy of regorafenib, fruquintinib, and TAS-102 in patients with metastatic colorectal cancer (mCRC). Using a network meta-analysis, we compared long-term survival outcomes (overall and progression-free surviva...

Ying-Yu Zhou, Shi-Qing Zhao, Xiao-Yi Zheng et al. · Frontiers in Oncology · 0 citations

Review Open access Sep 2026

PSMD14 as a translational target in cancer and beyond: from deubiquitination mechanisms to drug resistance and precision therapy

This review synthesizes current evidence demonstrating that PSMD14 drives therapeutic resistance across multiple malignancies by deubiquitinating and stabilizing key effectors such as E2F1, ALK2, IMPDH2, estrogen receptor α, and proteasomal components and critically evaluates the therapeutic landscape of PSMD14 inhibit...

Hong-Rui Liu, Liang Ma, Yi-Xuan Wang et al. · Cancer Drug Resistance · 0 citations

Review Open access Oct 2026

Immunomodulatory and Metabolic Effects of Ginsenosides Rg1/Rb1 in IBD, RA, and MASLD: Targeting Gut Microbiota–Autoimmunity Axis

Panax ginseng Meyer has been commonly used as a traditional herbal medicine in East Asia for millennia. Ginsenosides Rg1 and Rb1 are the primary pharmacologically active ingredients and exhibit broad therapeutic efficacy against immunometabolic disorders, including inflammatory bowel disease (IBD), metabolic dysfunctio...

Xin Mao, Zong-Xin Shao, Min Gao et al. · Microorganisms · 0 citations